Welcome to AstraZeneca United States

Beginning its journey in 1953, AstraZeneca became one of the first pharmaceutical companies operating in the United States

Quick Links

AstraZeneca in the US

AZ&You Blog

Medicines

Media

Careers

Contact

Latest News from AstraZeneca US

AstraZeneca to acquire Alexion

COVID-19 Information Hub

COVID-19 Resources for Patients and Caregivers Managing Chronic Conditions

New tezepelumab data continue to strengthen profile for a broad population of severe asthma patients

NAVIGATOR data published in New England Journal of Medicine, and latest data from tezepelumab clinical program presented at ATS 2021 International Conference

Tezepelumab reduced exacerbations by 77% in subgroup of patients with elevated inflammatory biomarkers in NAVIGATOR

Tezepelumab reduced exacerbations requiring hospitalization by 85%

IMFINZI and tremelimumab with chemotherapy demonstrated overall survival benefit in POSEIDON trial for 1st-line Stage IV non-small cell lung cancer

First Phase III trial to demonstrate overall survival benefit with tremelimumab

IMFINZI plus chemotherapy demonstrated progression-free survival benefit, but a trend in overall survival did not achieve statistical significance

FARXIGA approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type 2 diabetes

Approval is the most significant advancement in the treatment of chronic kidney disease in more than 20 years

Latest AZ&You Blog Articles